Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

10-Year study to watch how joint crystals affect health

NCT ID NCT07504146

Knowledge-focused Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 450 adults with gout, CPPD (a crystal-related joint disease), or osteoarthritis to see how crystal deposits in joints and blood vessels change over time. Participants receive routine care and undergo ultrasound and lab tests every six months for up to 10 years. The goal is to understand how these deposits respond to standard treatments and whether they are linked to heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Oct 2039

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients affected by gout, CPPD or osteoarthritis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

The inclusion criteria for CPPD patients are: * Patients diagnosed with CPPD disease according to the ACR/EULAR 2023 classification criteria. * Patients with evidence of asymptomatic CPPD on US or X-rays (not meeting the classification criteria) according to validated imaging definitions. * Aged older than 18 years. * Able to provide informed consent, according to requirements of local IRB/ethics committee. The inclusion criteria for gout patients are: * Patients diagnosed with gout according to the ACR/EULAR 2015 classification criteria. * Aged older than 18 years. * Able to provide informed consent, according to requirements of local IRB/ethics committee. The inclusion criteria for disease controls are: * A diagnosis of OA according to ACR classification criteria * No evidence of uric acid or calcium pyrophosphate deposits on US * Uric acid \< 6 mg/dL * Aged older than 18 years. * Able to provide informed consent, according to requirements of local IRB/ethics committee The exclusion criteria for gout/CPPD patients are: * Known history of other inflammatory arthropathies * Unable to provide informed consent, according to requirements of local IRB/ethics committee. The exclusion criteria for disease controls are: * Known history of other inflammatory arthropathies * Unable to provide informed consent, according to requirements of local IRB/ethics committee.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CPPD - calcium pyrophosphate deposition disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chondrocalcinosis gout osteoarthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CPPD - calcium pyrophosphate deposition disease Gout

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Ospedale Galeazzi-Sant'Ambrogio

    RECRUITING

    Milan, Milano, 20157, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.